IRIS Accounts Production v24.2.0.383 07181386 Board of Directors 1.4.23 31.3.24 31.3.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh071813862023-03-31071813862024-03-31071813862023-04-012024-03-31071813862022-03-31071813862022-04-012023-03-31071813862023-03-3107181386ns15:EnglandWales2023-04-012024-03-3107181386ns14:PoundSterling2023-04-012024-03-3107181386ns10:Director12023-04-012024-03-3107181386ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3107181386ns10:SmallEntities2023-04-012024-03-3107181386ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3107181386ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3107181386ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3107181386ns10:FullAccounts2023-04-012024-03-3107181386ns10:Director22023-04-012024-03-3107181386ns10:Director32023-04-012024-03-3107181386ns10:RegisteredOffice2023-04-012024-03-3107181386ns5:CurrentFinancialInstruments2024-03-3107181386ns5:CurrentFinancialInstruments2023-03-3107181386ns5:ShareCapital2024-03-3107181386ns5:ShareCapital2023-03-3107181386ns5:RetainedEarningsAccumulatedLosses2024-03-3107181386ns5:RetainedEarningsAccumulatedLosses2023-03-3107181386ns5:ComputerEquipment2023-04-012024-03-3107181386ns5:ComputerEquipment2023-03-3107181386ns5:ComputerEquipment2024-03-3107181386ns5:ComputerEquipment2023-03-3107181386ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-03-3107181386ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-3107181386ns5:WithinOneYear2024-03-3107181386ns5:WithinOneYear2023-03-3107181386ns5:BetweenOneFiveYears2024-03-3107181386ns5:BetweenOneFiveYears2023-03-3107181386ns5:AllPeriods2024-03-3107181386ns5:AllPeriods2023-03-31
REGISTERED NUMBER: 07181386 (England and Wales)















Unaudited Financial Statements for the Year Ended 31st March 2024

for

Advanced Global Health Limited

Advanced Global Health Limited (Registered number: 07181386)






Contents of the Financial Statements
for the Year Ended 31st March 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


Advanced Global Health Limited

Company Information
for the Year Ended 31st March 2024







DIRECTORS: J G Black
D J Fisher
A J Fisher





REGISTERED OFFICE: G03
30 Great Guildford Street
London
SE1 OHS





REGISTERED NUMBER: 07181386 (England and Wales)





ACCOUNTANTS: Sampson Fielding Ltd
34 - 35 Clarges Street
Mayfair
London
W1J 7EJ

Advanced Global Health Limited (Registered number: 07181386)

Balance Sheet
31st March 2024

31/3/24 31/3/23
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 570 1,469

CURRENT ASSETS
Stocks 274,265 216,704
Debtors 5 479,217 373,999
Cash at bank 324,765 184,558
1,078,247 775,261
CREDITORS
Amounts falling due within one year 6 581,278 435,600
NET CURRENT ASSETS 496,969 339,661
TOTAL ASSETS LESS CURRENT LIABILITIES 497,539 341,130

PROVISIONS FOR LIABILITIES 143 279
NET ASSETS 497,396 340,851

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 497,296 340,751
497,396 340,851

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 27th August 2024 and were signed on its behalf by:





J G Black - Director


Advanced Global Health Limited (Registered number: 07181386)

Notes to the Financial Statements
for the Year Ended 31st March 2024

1. STATUTORY INFORMATION

Advanced Global Health Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Significant judgements and estimates
Estimates of the useful economic lives of fixed assets have been made in order to include depreciation and amortisation rates comparable with the rate at which the value of the assets should be recognised in the Statement of Comprehensive Income. No other estimates of a material nature have been included in the accounts.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Computer equipment - straight line over 3 years

Tangible fixed assets under the cost model are stated at historic cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the costs of assets less their residual value over their estimated useful lives, using the straight-line method.

The asset's residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the Statement of Comprehensive Income.

Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Costs, which comprise direct production costs, are based on the method most appropriate to the type of inventory class, but usually on a first-in-first-out basis. Overheads are charged to profit or loss as incurred. Net realisable value is based on the estimated selling price less any estimated completion or selling costs.

When stocks are sold, the carrying amount of those stocks is recognised as an expense in the period in which the related revenue is recognised. The amount of any write-downs of stock to net realisable value and all losses of stocks are recognised as an expense in the period in which the write-down or loss occurs. The amount of any reversal of any write-down of stocks is recognised as a reduction in the amount of inventories recognised as an expense in the period in which the reversal occurs.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Advanced Global Health Limited (Registered number: 07181386)

Notes to the Financial Statements - continued
for the Year Ended 31st March 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
The Company's functional and presentational currency is GBP.

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and where non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Comprehensive Income except when deferred in other comprehensive income as qualifying cash flow hedges.

Pension costs and other post-retirement benefits
The Company operates a defined contribution pension plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recongised as an expense in the Statement of Comprehensive Income when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

Trade and other debtors
Trade and other debtors that are receivable within one year and do not constitute a financing transaction are recorded at the undiscounted amount expected to be received, net of impairment. Those that are receivable after more than one year or that constitute a financing transaction are recorded initially at fair value less transaction costs and subsequently at amortised cost, net of impairment.

Advanced Global Health Limited (Registered number: 07181386)

Notes to the Financial Statements - continued
for the Year Ended 31st March 2024

2. ACCOUNTING POLICIES - continued

Trade and other creditors
Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method unless the effect of discounting would be immaterial, in which case they are stated at cost.

Financial instruments
Debt instruments (other than those wholly repayable or receivable within one year), including loans and other amounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade payables or receivable, are measured, initially and subsequentially, at the undiscounted amount of the cash or other consideration, expected to be paid or received. However if the arrangements of a short term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms of financed at a rate of interest that is not market rate or in case of an outright short term loan not at market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evident of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of Comprehensive Income.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate, which is approximation of the amount that the Company would receive for the asset if it were to be sold at the Balance Sheet date.

Financial assets and liabilities are offset and the net amount reported in the Balance Sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and in hand and short term deposits with an original maturity date of three months or less.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 11 (2023 - 10 ) .

4. TANGIBLE FIXED ASSETS
Computer
equipment
£   
COST
At 1st April 2023
and 31st March 2024 5,232
DEPRECIATION
At 1st April 2023 3,763
Charge for year 899
At 31st March 2024 4,662
NET BOOK VALUE
At 31st March 2024 570
At 31st March 2023 1,469

Advanced Global Health Limited (Registered number: 07181386)

Notes to the Financial Statements - continued
for the Year Ended 31st March 2024

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31/3/24 31/3/23
£    £   
Trade debtors 458,062 346,684
Other debtors 6,199 6,444
Prepayments 14,956 20,871
479,217 373,999

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31/3/24 31/3/23
£    £   
Trade creditors 239,284 296,014
Tax 86,102 19,858
R&D tax payable - 26,099
Other creditors 1,104 3,342
VAT 57,613 40,397
Directors' current accounts 2,381 1,795
Deferred income 161,530 -
Accrued expenses 33,264 48,095
581,278 435,600

7. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
31/3/24 31/3/23
£    £   
Within one year 16,023 26,814
Between one and five years - 16,023
16,023 42,837